AEON Biopharma, Inc. (AEON): Entry into a Material Definitive Agreement
AEON Biopharma, Inc. (AEON) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-4.4 6 aeon-20260713xex4d4.htm EX-4.4 M2561538.DOC;3 Exhibit 4.4 EXECUTION VERSION WARRANT AGENCY AGREEMENT THIS WARRANT AGENCY AGREEMENT (this “Agreement”), dated as of July 15, 2026, is entered into by and between AEON Biopharma, Inc., a Delaware corporation (the “Company”),
How this was made
The 30-second read
Why it matters
This is an operational/legal step enabling issuance, registration, transfer, and exercise of warrants, which can influence dilution expectations but does not, by itself, provide new capital-raise economics in the provided text.
Market read
The filing supports the mechanics of a warrant program referenced in AEON’s S-1, which may matter for dilution modeling but lacks new pricing/proceeds details here.
What to watch
Traders should look for the separate financing/pricing terms (exercise prices, number of warrants, proceeds) which are not present in the excerpt, as those would drive dilution and valuation more than the agency mechanics.
Background
AEON’s 8-K Item 1.01 attaches a warrant agency agreement with Continental Stock Transfer & Trust Company, referencing an S-1 registration for pre-funded and milestone warrants.
Ticker impact
AEON filed an 8-K disclosing entry into a warrant agency agreement tied to its S-1 registration of pre-funded and milestone warrants.
Likely modest, mostly sentiment and dilution-overhang driven, unless paired with a separate pricing/financing announcement not included here.
The text is an exhibit describing warrant agent mechanics (registration, countersignature, exercise/cashless provisions) rather than new economics, pricing, or a completed financing size.
Market effects
Limited read-across; warrant administration details are company-specific and not a sector-wide regulatory or clinical catalyst.
None indicated.
None indicated.
Counterpoint
If the warrants are already anticipated from the S-1, the incremental impact may be minimal and the stock reaction could be muted.
Key entities
- issuerAEON Biopharma, Inc.
Company entering the warrant agency agreement for pre-funded and milestone warrants.
- warrant_agentContinental Stock Transfer & Trust Company
Warrant agent appointed to administer warrant issuance, registration, and exercise mechanics.
